1252679-52-9
| 中文名称 | 1252679-52-9 |
|---|---|
| 中文同义词 | 化合物 T15603;N-(5-(叔丁基)-2-甲氧基-3-(甲基磺酰胺基)苯基)-2-(4-(2-吗啉乙氧基)萘-1-基)-2-氧代乙酰胺盐酸盐 |
| 英文名称 | ITX-5061 HCl |
| 英文同义词 | ITX-5061 HCl;ITX-5061;ITX-5061 hydrochloride (ITX5061);ITX-5061 hydrochloride;ITX506 HCl;N-(5-(tert-Butyl)-2-methoxy-3-(methylsulfonamido)phenyl)-2-(4-(2-morpholinoethoxy)naphthalen-1-yl)-2-oxoacetamide hydrochloride , ITX5061 |
| CAS号 | 1252679-52-9 |
| 分子式 | C30H38ClN3O7S |
| 分子量 | 620.16 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1252679-52-9.mol |
| 结构式 |  |
1252679-52-9 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 二甲基亚砜：≥ 83.3 mg/ml（134.32 mM） |
| 形态 | 固体 |
| 颜色 | 浅黄至浅棕色 |
p38 MAPK, SR-B1
ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1). Treatment of ITX5061 (30 mg/kg/day) for mice results in a 50% increase in HDL-C levels compare to baseline. ApoA-I levels are moderately (+15 %) but significantly increased in ITX5061-treated HuAITg mice, compare to mice receive vehicle. ITX5061 significantly decreases HDL-CE catabolism with an FCR of 1.86±0.40 pools/d vs 2.47±0.26 pools/d in the control group (P<0.05), while calculated production rates are identical in both groups (129±24 μg/g/d vs 129±16 μg/g/d). Moreover, accumulation of [ 3 H] CE in the liver is significantly lower in ITX5061-treated mice indicating that increased HDL-CE levels are due to reduced uptake by the liver.
安全信息
| 海关编码 | 2933998090 |
|---|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/08/19 | HY-19900 | ITX5061 | 1 mg | 2600元 | |
| 2024/08/19 | HY-19900 | 1252679-52-9 ITX5061 | 1252679-52-9 | 5mg | 5200元 |